Skip to main content
  • Cost-effectiveness analysis of VTE prophylaxis in patients undergoing craniotomy for tumor.

    Final Number:

    Minal Jain MD, MPH; Kristopher T. Kimmell MD; Dushyant Damania MD; Jignesh H. Patel PharmD, BS; Anunaya Jain MD, MCEM, MBA; Babak S. Jahromi MD PhD FRCSC

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Studies have evaluated various regimens for prophylaxis against VTE in neurosurgical patients, but optimal choice of VTE prophylaxis in patients with brain tumor remains controversial. Our aim was to perform a cost-effectiveness analysis (CEA) of various prophylactic measures employed to reduce VTE in patients undergoing craniotomy for brain tumor.

    Methods: We searched for studies examining VTE prophylaxis in patients undergoing craniotomy for brain tumor between 1973 and 2013. We restricted analysis to studies which examined either mechanical prophylaxis (MP) alone, MP + low-molecular-weight heparin (LMWH) or MP + unfractionated heparin (UFH). Each study had at least 30 days follow-up, and specified whether VTE was symptomatic. Development of symptomatic VTE and/or ICH within 30-days of craniotomy was considered the end-point. Outcome was reported in QALYs. Cost data was collected from Healthcare Cost and Utilization Project (HCUP) database and other published sources (reported in 2013 US$).

    Results: We identified 11 studies that satisfied the inclusion criteria for CEA. The probability of VTE was 1.1% in the UFH arm, 2.56% in LMWH arm, and 2.59% in the MP arm. The corresponding probabilities of developing ICH were 0.37%, 2.79%, and 0%, respectively. The average cost/QALY was $299.34 for UFH, $333.20 for MP and $993.92 for LMWH.

    Conclusions: Our model suggests that in patients undergoing craniotomy for brain tumor, UFH is the most cost-effective VTE prophylaxis.

    Patient Care: This facilitates the most cost effective way of using various prophylaxis measure to prevent VTE in patients undergoing craniotomy for tumor.

    Learning Objectives: Learn about the most cost effective measure to prevent VTE in tumor patients undergoing craniotomy.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy